On May 17, 2019, the US Food and Drug Administration (FDA) expanded the indication for the glucagon-like peptide-2 analog teduglutide (Gattex, Takeda) for injection in patients 1 year of age and older with short bowel syndrome (SBS) who require additional intravenous parenteral support. Teduglutide was approved for adults with SBS in 2012.
展开▼
